UNSPSC 51294404: Befuraline

This classification denotes a phosphodiesterase inhibitor and antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 787AQ35GHR. European Medicines Agency schedules Befuraline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05683MIG. Befuraline generally arises in the molecular formula C20H20N2O2.

UNSPSC 51294404 Befuraline, a Commodity code, describes pharmaceutical products that state and local governments procure for public health, emergency response, and community health programs. Recent solicitations under this code show state and local buyers purchasing naloxone and drug deactivation systems for emergency medical use, generic pharmaceuticals and over-the-counter products through cooperative purchasing arrangements, and direct-to-manufacturer prescription fulfillment programs. The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The scope spans emergency response medications, generic pharmaceuticals distributed through authorized wholesale channels, and pharmaceutical supply chain optimization initiatives that bypass traditional pharmacy benefit manager intermediaries.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with bids due July 26, 2023. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, signaling the state's interest in restructuring pharmaceutical procurement outside traditional PBM and GPO channels. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement and serving participating state and local facilities including Oregon, released RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026 and contract effectiveness set for July 1, 2026; vendors must maintain relationships with authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) and comply with cGMP and Drug Supply Chain Security Act requirements.